Lux Biosciences sets up in Europe
New Jersey, USA-based Lux Biosciences, a privately-held biotechnology company specialized in the field of ophthalmic diseases, say that it has established Lux Biosciences GmbH in Frankfurt, Germany, as a wholly-owned subsidiary with the mission to create an infrastructure for the company's European activities.
It adds that, by developing a product pipeline in the USA and Europe simultaneously, Lux intends to create significant synergies in drug and market development. In addition, it says, this effort builds on Lux' recent milestones, including the following:
- in May 2006, Lux secured from its partner Isotechnika an exclusive, worldwide license for LX211, its next-generation calcineurin inhibitor, for ophthalmic treatments. This compound is currently entering pivotal-stage clinical development in uveitis; and
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze